LATEST NEWS
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in…
VIDEO highlights from @montypal 2024 Annual Oncology and Research Symposium https://oncologytube.com/tag/moasc-2024-oncology-summit/ featuring presentations from @KarenReckampMD @jtmoyers @Dr_RShatsky @arafflemd Heinz-Josef Lenz @akhtari_mojtaba @DrLizBrem @UCIrvineHealth @CancerCenter @CityofHopeCME…
Check out the incredible young investigators from @cityofhope who presented their work at #MOASC24! A huge thanks to @MOASC_Office, our state society, & @oncologytube for offering them an opportunity to shine! @SalvadorjcMD @AlexisLevee @NazliDizman @NickSalgia…
Oncology Conference Videos
Oncology News
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…
Brentuximab Vedotin, Ipilimumab, + Nivolumab Combination Hodgkin Lymphoma [ASH 2023]
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…
Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023]
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
In the realm of advancements in CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL),…
Elranatamab for Black Patients with Relapsed Multiple Myeloma [ASH 2023]
Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with…
Practice patterns for sequential use of antibody-drug conjugate after antibody-drug
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a…
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews]
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews…
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set…